![]() FDA clears expanded labeling for Preceptis Medical’s ear tube system.Verily’s Onduo, Sword Health collaborate on virtual care.CathVision closes $7.2M financing round for electrophysiology recording tech. ![]() Tandem Diabetes Care delivers 1 million insulin boluses using t:connect mobile app.Henry Schein makes $400M increase to share repurchase plan.Caregility, Eko partner to bring smart stethoscope to telehealth platform.Report: 3M faces losses of $100B in earplug lawsuits.RefleXion expands footprint through multi-system contract with Select Healthcare.EchoNous partners with Samsung on AI-guided ultrasound.MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was down slightly.įiled Under: Dialysis, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Outset Medical Shares in OM were up 3.43% to $40.37 apiece in mid-morning trading. Ahmed joined the company in May 2020 as VP and controller and has served as interim chief financial officer since July 16. The company also announced that Nabeel Ahmed has transitioned to the permanent role of chief financial officer, effective immediately. Outset Medical said it projects full-year revenue to be in the range of $97 million to $100 million. ![]() We remain confident in our ability to execute on each of our key strategic initiatives for 2021 and in our long-term growth prospects.” “With new home console bookings up substantially in the second quarter, and both current and new customers purchasing Tablo for acute use, our integrated commercial strategy is working as expected. “In the first half of 2021, we delivered best-in-class revenue growth and steady gross margin improvement driven by a team that is dedicated to, and united around, transforming the dialysis experience for patients and providers,” president and CEO Leslie Trigg said in a news release out yesterday evening. The San Jose, Calif.–based maker of the Tablo is a dialysis machine reported losses of -$30.2 million, or -66¢ per share, on sales of $25.2 million for the three months ended June 30, 2021, for a sales growth of 114.75% compared with Q2 2020.Īdjusted to exclude one-time items, earnings per share were -57¢, 12¢ ahead of The Street, where analysts were looking for sales of $23.49 million. Outset Medical (NSDQ:OM) posted second-quarter results this week that beat the overall consensus on Wall Street. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |